Objectives
Our objective was to test the hypothesis that local delivery of a WNT protein therapeutic would support osseointegration of an unstable implant placed into an oversized osteotomy and subjected to functional loading.
Materials and methods
Using a split‐mouth design in an ovariectomized (OVX) rat model, 50 titanium implants were placed in oversized osteotomies. Implants were subjected to functional loading. One‐half of the implants were treated with a liposomal formulation of WNT3A protein (L‐WNT3A); the other half received an identical liposomal formulation containing phosphate‐buffered saline (PBS). Finite element modeling estimated peri‐implant strains caused by functional loading. Histological, molecular, cellular, and quantitative micro‐computed tomographic (µCT) imaging analyses were performed on samples from post‐implant days (PID) 3, 7, and 14. Lateral implant stability was quantified at PID 7 and 14.
Results
Finite element analyses predicted levels of peri‐implant strains incompatible with new bone formation. Micro‐CT imaging, histological, and quantitative immunohistochemical (IHC) analyses confirmed that PBS‐treated implants underwent fibrous encapsulation. In those cases where the peri‐implant environment was treated with L‐WNT3A, µCT imaging, histological, and quantitative IHC analyses demonstrated a significant increase in expression of proliferative (PCNA) and osteogenic (Runx2, Osterix) markers. One week after L‐WNT3A treatment, new bone formation was evident, and two weeks later, L‐WNT3A‐treated gaps had a stiffer interface compared to PBS‐treated gaps.
Conclusion
In a rat model, unstable implants undergo fibrous encapsulation. If the same unstable implants are treated with L‐WNT3A at the time of placement, then it results in significantly more peri‐implant bone and greater interfacial stiffness.